- Home
- LRE vs RANI Comparison
LRE vs RANI Comparison
Compare LRE & RANI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LRE
- RANI
- Stock Information
- Founded
- LRE 2001
- RANI 2012
- Country
- LRE Japan
- RANI United States
- Employees
- LRE 70
- RANI N/A
- Industry
- LRE
- RANI Medicinal Chemicals and Botanical Products
- Sector
- LRE
- RANI Health Care
- Exchange
- LRE Nasdaq
- RANI Nasdaq
- Market Cap
- LRE 24.4M
- RANI 17.0M
- IPO Year
- LRE 2023
- RANI 2021
- Fundamental
- Price
- LRE $1.76
- RANI $0.65
- Analyst Decision
- LRE
- RANI Strong Buy
- Analyst Count
- LRE 0
- RANI 4
- Target Price
- LRE N/A
- RANI $7.75
- AVG Volume (30 Days)
- LRE 11.2K
- RANI 327.7K
- Earning Date
- LRE 01-01-0001
- RANI 08-05-2025
- Dividend Yield
- LRE N/A
- RANI N/A
- EPS Growth
- LRE N/A
- RANI N/A
- EPS
- LRE N/A
- RANI N/A
- Revenue
- LRE $110,330,328.00
- RANI $1,200,000.00
- Revenue This Year
- LRE N/A
- RANI N/A
- Revenue Next Year
- LRE N/A
- RANI N/A
- P/E Ratio
- LRE N/A
- RANI N/A
- Revenue Growth
- LRE 3.92
- RANI N/A
- 52 Week Low
- LRE $1.10
- RANI $0.46
- 52 Week High
- LRE $2.49
- RANI $4.19
- Technical
- Relative Strength Index (RSI)
- LRE 54.52
- RANI 61.01
- Support Level
- LRE $1.71
- RANI $0.52
- Resistance Level
- LRE $1.78
- RANI $0.68
- Average True Range (ATR)
- LRE 0.08
- RANI 0.04
- MACD
- LRE -0.01
- RANI 0.03
- Stochastic Oscillator
- LRE 28.78
- RANI 83.92
About LRE Lead Real Estate Co. Ltd
Lead Real Estate Co Ltd operates as a developer of luxury residential properties, including single-family homes and condominiums, across Tokyo, Kanagawa prefecture, and Sapporo. The company also operates hotels in Tokyo and leases apartment building units to individual customers in Japan and Dallas, Texas. Predominantly, its revenue is generated from developing and selling single-family homes and condominiums. The company's sole operating segment is real estate sales. Geographically, it derives revenue from Japan.
About RANI Rani Therapeutics Holdings Inc.
Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads in liquid form with high bioavailability.